Thus, the data from our group and others indicate that CB2 agonists are a promising strategy for the treatment of peripheral neuropathy caused by OXA, with a potential broader impact on neuropathies caused by other anticancer drugs. This evidence concerns the gene CNR2 and neuropathy.